Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation. Bone Marrow Transplant 2012 Jan;47(1):146-8

Date

03/02/2011

Pubmed ID

21358681

DOI

10.1038/bmt.2011.18

Scopus ID

2-s2.0-84855736330 (requires institutional sign-in at Scopus site)   5 Citations

Author List

Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M

Author

Mehdi H. Hamadani MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adult
Aged
Antineoplastic Agents
Boronic Acids
Bortezomib
Female
Follow-Up Studies
Humans
Immunosuppressive Agents
Male
Middle Aged
Multiple Myeloma
Peripheral Blood Stem Cell Transplantation
Pyrazines
Retrospective Studies
Thalidomide
Transplantation, Autologous